Health · Pharma & Biotech · 3 hrs ago
Bristol Myers reports two Phase 3 trial successes
Bristol Myers Squibb reported two successful Phase 3 clinical trials on Monday.
The trials involved drugs for fibrosis and drugs from RayzeBio.
One of the experimental drugs had recently faced safety issues.
Phase 3 trials test treatments in large groups of people and are a late stage of drug development.
The reported results are positive trial outcomes, but the details are not provided here.
The results matter because they could support further development of the drugs.
No next steps are specified.
Bristol Myers Squibb reported two Phase 3 trial successes on Monday morning.
The reported successes involved fibrosis and RayzeBio drugs.
One experimental drug had recently encountered safety issues.
The article does not name the drugs or provide trial results.
- Who
- Bristol Myers Squibb.
- What
- It reported two Phase 3 trial successes.
- When
- Monday morning; the article was published on October 12, 2026.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
This story does not have a timeline yet.
- Company
- Bristol Myers Squibb
- Trial stage
- Phase 3
- Number of reported successes
- Two
- Areas mentioned
- Fibrosis and RayzeBio drugs
Sources
Related news
FDA approves Asahi Kasei’s herpes treatment
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Aficamten Improves Exercise Capacity in Nonobstructive Heart Condition Trial
GLP-1 drugs may have a role in addiction care, but questions remain
Retatrutide led to major weight loss in a trial involving adults with type 2 diabetes
Lenacapavir and cabotegravir controlled HIV in a small patient study
EU approves evolocumab for adults at high cardiovascular risk
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Brazil suspends Peptistrong supplement and orders all batches recalled
